home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Astria Therapeutics, Inc. - Common Stock (NQ:ATXS)

12.58 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Astria Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Astria Therapeutics Commences Initial-Stage Skin Disorder Study, Sees Preliminary Data By Year-end ↗

August 04, 2022

Astria Therapeutics (NASDAQ: ATXS) announced initiation of a Phase 1a clinical trial of STAR-0215 in healthy subjects. STAR-0215 is designed to provide long-acting, effective attack prevention for...

Via Benzinga

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema

August 04, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Present at Upcoming Wedbush PacGrow Healthcare Conference 2022

August 03, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 02, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Recap Of Thursday's Biotech Catalysts - End of The Day Summary ↗

July 28, 2022

Via Benzinga

Astria Therapeutics Gets FDA Nod For Initial-Stage Hereditary Angioedema Study ↗

July 28, 2022

The U.S. Food and Drug Administration (FDA) announced clearance to Astria Therapeutics’ (NASDAQ: ATXS) Investigational New Drug (IND) application for STAR-0215 in the treatment of Hereditary Angioedema...

Via Benzinga

Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗

July 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema

July 28, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Names Chris Morabito Chief Medical Officer

July 15, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Participate in Virtual Fireside Chat at Upcoming H.C. Wainwright 1st Annual Hereditary Angioedema Conference

July 14, 2022

From Astria Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

July 08, 2022

Gainers Passage Bio (NASDAQ:PASG) shares moved upwards by 7.7% to $2.66 during Friday's after-market session. The market value of their outstanding shares is at $144.4 million.

Via Benzinga

Astria Therapeutics Presents New Preclinical Data Showing Differentiated Profile of STAR-0215, in Development for Treatment of Hereditary Angioedema

July 05, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Present New Preclinical STAR-0215 Data at the European Academy of Allergy and Clinical Immunology 2022 Hybrid Congress

June 23, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

June 03, 2022

From Astria Therapeutics

Via Business Wire

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 02, 2022

From Astria Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

June 01, 2022

Via Benzinga

62 Biggest Movers From Yesterday ↗

June 02, 2022

Gainers Missfresh Limited (NASDAQ: MF) jumped 51.1% to close at $0.2450 on Wednesday.

Via Benzinga

Astria Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

May 12, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Present STAR-0215 Data at the 2022 Fc Receptor and IgG Targeted Therapies Conference

April 21, 2022

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 04, 2022

From Astria Therapeutics, Inc.

Via Business Wire

(ATXS) - Analyzing Astria Therapeutics Inc. - Common Stock's Short Interest ↗

March 21, 2022

Astria Therapeutics Inc. - Common Stock's (NASDAQ:ATXS) short percent of float has fallen 18.83% since its last report. The company recently reported that it has 150.40 thousand...

Via Benzinga

Astria Therapeutics to Present STAR-0215 Data at the 2022 American Academy of Allergy, Asthma and Immunology Annual Meeting

February 18, 2022

From Astria Therapeutics, Inc.

Via Business Wire

50 Biggest Movers From Friday ↗

February 07, 2022

Also check out this: Executives Sell Over $45M Of 5 Stocks Losers Ra Medical Systems, Inc. (NYSE: RMED) shares dipped 48.8% to close at $0.3599 on Friday after the...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 04, 2022

Gainers iRadimed (NASDAQ:IRMD) stock rose 15.0% to $45.19 during Friday's regular session. Trading volume for iRadimed's stock is 94.1K as of 12:30 EST. This is...

Via Benzinga

64 Biggest Movers From Yesterday ↗

February 01, 2022

Gainers Calithera Biosciences, Inc. (NASDAQ: CALA) shares surged 55.7% to settle at $0.65 on Monday after Ladenburg Thalmann initiated coverage on the stock with a...

Via Benzinga

Astria Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

November 10, 2021

From Astria Therapeutics, Inc.

Via Business Wire

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance ↗

November 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...

Via Benzinga

Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

November 09, 2021

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Presents New Preclinical Data Showing the Differentiated Profile of STAR-0215, in Development to Treat Hereditary Angioedema

November 05, 2021

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Developments on Wednesday, November 10

October 27, 2021

From Astria Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com